Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy (NADERIN-BC)

Medical Rehabilitation in Oncology: Prophylaxis of Hematologic and Immunologic Complications Using Naderin During First-Line Chemotherapy of Breast Cancer

The goal of this clinical trial is to learn if Naderin works to prevent low white blood cell counts in people with breast cancer receiving first-line chemotherapy. The main questions it aims to answer are:

1. Does taking Naderin lower the number of people who get low white blood cell counts during chemotherapy?
2. Does taking Naderin help people finish all of their chemotherapy treatments without interruptions? Researchers will compare people who receive chemotherapy with Naderin to people who receive chemotherapy alone to see if Naderin helps prevent low white blood cell counts.

Participants will:

Receive standard AC chemotherapy for breast cancer Either receive Naderin along with chemotherapy or receive chemotherapy alone Have regular blood tests to check white blood cell counts Complete all 4 chemotherapy cycles

Key finding: The study found that 14 out of 100 people who received Naderin developed low white blood cell counts, compared to 39 out of 100 people who did not receive Naderin.

Study Overview

• Status: Completed
• Conditions: Breast Cancer; Leukopenia; Hematologic Disorder; Chemotherapy-Induced Myelosuppression
• Intervention / Treatment: Drug: Naderin; Drug: AC Chemotherapy

Detailed Description

This was a prospective, open-label, interventional study conducted at the Kazakh Scientific Research Institute of Oncology and Radiology in Almaty, Republic of Kazakhstan, in collaboration with KazNMU and the Almaty Oncology Center. The study evaluated the prophylactic use of Naderin during first-line AC chemotherapy for breast cancer.

Participant Allocation:

A total of 79 participants with breast cancer receiving first-line chemotherapy were enrolled and assigned to two groups. The main group, consisting of 38 participants, received AC chemotherapy with Naderin as an adjunct prophylactic agent. The control group, consisting of 41 participants, received AC chemotherapy alone. Allocation was not randomized; participants were assigned based on consecutive enrollment according to clinical availability and patient consent.

Intervention Details:

All participants received standard AC chemotherapy consisting of doxorubicin and cyclophosphamide administered intravenously for 4 planned cycles at standard institutional dosing. Participants in the main group additionally received Naderin, a sodium deoxyribonucleate immunomodulatory agent, administered locally alongside each chemotherapy cycle. Naderin functions by activating cellular and humoral immunity, stimulating reparative processes, and exhibiting anti-inflammatory properties.

Outcome Measures:

The primary outcome was the incidence of leukopenia, defined as white blood cell count below the institutional lower limit of normal, measured by complete blood counts during chemotherapy cycles. Secondary outcomes included completion rate of all 4 planned chemotherapy cycles, need for chemotherapy interruption or discontinuation, requirement for colony-stimulating factor administration, quality of life assessment using a validated instrument, and all-cause mortality during the study period.

Assessment Schedule:

At baseline, participants underwent complete blood count, medical history documentation, and quality of life assessment. During each of the 4 chemotherapy cycles, complete blood counts were performed and adverse events were monitored. At the end of treatment, complete blood count, quality of life assessment, and treatment completion status were recorded. Follow-up included survival status documentation.

Statistical Analysis:

The primary comparison between groups for leukopenia incidence was performed using the chi-square test with a significance level set at p < 0.05.

Ethical Considerations:

The study was conducted in accordance with the Declaration of Helsinki. Institutional review board approval was obtained, and all participants provided written informed consent prior to enrollment.

• Study Type: Interventional
• Enrollment (Actual): 79
• Phase: Phase 2; Phase 3

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Confirmed histological diagnosis of breast cancer

Receiving first-line AC chemotherapy (doxorubicin + cyclophosphamide)

Age 18 years or older

Female sex

Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Adequate bone marrow function (absolute neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L)

Adequate hepatic function (transaminases ≤ 2.5 × upper limit of normal)

Adequate renal function (creatinine ≤ 1.5 × upper limit of normal)

Normal cardiac function (left ventricular ejection fraction ≥ 50%)

Willing and able to provide written informed consent

Exclusion Criteria:

• Previous chemotherapy or radiotherapy for breast cancer

History of other malignant neoplasms (except non-melanoma skin cancer or carcinoma in situ of the cervix)

Severe organ dysfunction (cardiac, hepatic, renal, pulmonary)

Active infection requiring systemic therapy

Known hypersensitivity to Naderin or any of its components

Known hypersensitivity to doxorubicin, cyclophosphamide, or any excipients

Pregnancy or breastfeeding

Psychiatric or cognitive impairment that would interfere with study participation

Participation in another interventional clinical trial within 30 days prior to enrollment

Any condition that, in the investigator's opinion, would compromise participant safety or interfere with study objectives

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Naderin prophylaxis Group; Participants in this arm receive standard first-line AC chemotherapy (doxorubicin + cyclophosphamide) for 4 cycles. In addition, participants receive Naderin (sodium deoxyribonucleate) as an adjunct prophylactic agent administered locally alongside each chemotherapy cycle to prevent hematologic and immunologic complications.	Drug: Naderin; Naderin is an immunomodulatory agent containing sodium deoxyribonucleate. It activates cellular and humoral immunity, stimulates reparative processes, and exhibits anti-inflammatory properties. It is administered locally alongside each chemotherapy cycle as prophylaxis against hematologic and immunologic complications. The agent is rapidly absorbed upon administration, distributed through lymphatic pathways to organs and tissues, and excreted primarily via the kidneys.; Other Names: Sodium Deoxyribonucleate; Sodium nucleinate
Active Comparator: Chemotherapy alone Group; Participants in this arm receive standard first-line AC chemotherapy (doxorubicin + cyclophosphamide) for 4 cycles. Participants do not receive Naderin or any other prophylactic immunomodulatory agent. This group serves as the active comparator to evaluate the prophylactic effect of Naderin on hematologic complications.	Drug: AC Chemotherapy; Standard first-line chemotherapy regimen consisting of doxorubicin (an anthracycline antibiotic) and cyclophosphamide (an alkylating agent). Administered intravenously for 4 cycles at standard institutional dosing. This is the backbone chemotherapy regimen for both study arms, with the experimental arm receiving Naderin as an adjunct prophylactic agent; Other Names: Doxorubicin and Cyclophosphamide

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of leukopenia during chemotherapy	Proportion of participants who develop leukopenia (white blood cell count below the institutional lower limit of normal) during any of the 4 chemotherapy cycles. Leukopenia is defined as a decrease in circulating white blood cells below 4.0 × 10⁹/L (or per institutional laboratory reference range)	Through chemotherapy completion, up to 4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Chemotherapy completion rate	Proportion of participants who successfully complete all 4 planned cycles of AC chemotherapy without interruption, dose reduction, or premature discontinuation.	At the end of treatment, up to 4 months
Rate of chemotherapy interruption	Proportion of participants requiring chemotherapy interruption, dose delay, or premature discontinuation due to hematologic complications or other adverse events.	Through chemotherapy completion, up to 4 months
Requirement for colony-stimulating factors	Proportion of participants requiring administration of granulocyte colony-stimulating factors (G-CSF) for management of chemotherapy-induced neutropenia.	Through chemotherapy completion, up to 4 months
Quality of Life assessment	Change in quality of life scores measured using a validated instrument (specific instrument not specified in publication) from baseline to end of treatment.	Baseline and at end of treatment, up to 4 months
All-cause mortality	Proportion of participants who died from any cause during the study period.	Through study completion, up to 12 months

Collaborators and Investigators

• Sponsor: MIPO Clinic
• Collaborators: Asfendiyarov Kazakh National Medical University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2014
• Primary Completion (Actual): December 31, 2015
• Study Completion (Actual): December 1, 2016

Study Registration Dates

• First Submitted: June 22, 2026
• First Submitted That Met QC Criteria: June 22, 2026
• First Posted (Actual): June 26, 2026

Study Record Updates

• Last Update Posted (Actual): June 26, 2026
• Last Update Submitted That Met QC Criteria: June 22, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: breast cancer; chemotherapy; prophylaxis; immunomodulation; medical rehabilitation; leukopenia; Naderin; hematological complications; AC chemotherapy; sodium deoxyribonucleate
• Additional Relevant MeSH Terms: Cytopenia; Neoplasms by Site; Neoplasms; Leukocyte Disorders; Skin Diseases; Breast Diseases; Skin and Connective Tissue Diseases; Hemic and Lymphatic Diseases; Breast Neoplasms; Hematologic Diseases; Leukopenia; Organic Chemicals; Hydrocarbons; Hydrocarbons, Cyclic; Carbohydrates; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Polycyclic Compounds; Glycosides; Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Phosphoramides; Organophosphorus Compounds; Anthracyclines; Naphthacenes; Aminoglycosides; Daunorubicin; Cyclophosphamide; Doxorubicin; sodium nucleinate
• Other Study ID Numbers: 7; Grant of KazNMU 2012 (Other Grant/Funding Number: KazNMU)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No